Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

JACC: Cardiovascular Interventions

Volumn 9, Issue 20, 2016, Pages 2124-2133

  Giustino, Gennaro ^a   Mehran, Roxana ^a   Veltkamp, Roland ^b   Faggioni, Michela ^a   Baber, Usman ^a   Dangas, George D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

embolic protection; stroke; TAVR

Indexed keywords

AORTA STENOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY RISK; DEVICE SAFETY; EMBOLIC PROTECTION DEVICE; EMBOLISM PREVENTION; GENERAL CONDITION DETERIORATION; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MONTREAL COGNITIVE ASSESSMENT; MULTICENTER STUDY (TOPIC); NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSCATHETER AORTIC VALVE IMPLANTATION; VASCULAR ACCESS; ADVERSE EFFECTS; AORTIC VALVE; AORTIC VALVE STENOSIS; CHI SQUARE DISTRIBUTION; DEVICES; FEMALE; INTRACRANIAL EMBOLISM; MALE; MORTALITY; ODDS RATIO; PATHOPHYSIOLOGY; PROSTHESIS DESIGN; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; CHI-SQUARE DISTRIBUTION; EMBOLIC PROTECTION DEVICES; FEMALE; HUMANS; INTRACRANIAL EMBOLISM; MALE; ODDS RATIO; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 84992709429     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.07.024     Document Type: Article

References (24)

1. 1 Smith, C.R., Leon, M.B., Mack, M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
2. 2 Giustino, G., Dangas, G.D., Stroke prevention in valvular heart disease: from the procedure to long-term management. EuroIntervention 11:Suppl W (2015), W26–W31.
3. 3 Nombela-Franco, L., Webb, J.G., de Jaegere, P.P., et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 126 (2012), 3041–3053.
4. 4 Mastoris, I., Schoos, M.M., Dangas, G.D., Mehran, R., Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. Clin Cardiol 37 (2014), 756–764.
5. 5 Mack, M.J., Brennan, J.M., Brindis, R., et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 310 (2013), 2069–2077.
6. 6 Zimpfer, D., Czerny, M., Kilo, J., et al. Cognitive deficit after aortic valve replacement. Ann Thorac Surg 74 (2002), 407–412.
7. 7 Uekermann, J., Suchan, B., Daum, I., Kseibi, S., Perthel, M., Laas, J., Neuropsychological deficits after mechanical aortic valve replacement. J Heart Valve Dis 14 (2005), 338–343.
8. 8 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
9. 9 Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
10. 10 Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5 (2005), 1–10.
11. 11 Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
12. 12 Lansky, A.J., Schofer, J., Tchetche, D., et al. A prospective randomized evaluation of the Triguard HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation: results from the DEFLECT III trial. Eur Heart J 36 (2015), 2070–2078.
13. 13 Wendt, D., Kleinbongard, P., Knipp, S., et al. Intraaortic protection from embolization in patients undergoing transaortic transcatheter aortic valve implantation. Ann Thorac Surg 100 (2015), 686–691.
14. 14 Kahlert, P., Al-Rashid, F., Dottger, P., et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation 126 (2012), 1245–1255.
15. 15 Rodes-Cabau, J., Puri, R., Filtering the truth behind cerebral embolization during transcatheter aortic valve replacement. J Am Coll Cardiol Intv 8 (2015), 725–727.
16. 16 Van Mieghem, N.M., El Faquir, N., Rahhab, Z., et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. J Am Coll Cardiol Intv 8 (2015), 718–724.
17. 17 Sun, X., Lindsay, J., Monsein, L.H., Hill, P.C., Corso, P.J., Silent brain injury after cardiac surgery: a review: cognitive dysfunction and magnetic resonance imaging diffusion-weighted imaging findings. J Am Coll Cardiol 60 (2012), 791–797.
18. 18 Vogt, G., Laage, R., Shuaib, A., Schneider, A., Initial lesion volume is an independent predictor of clinical stroke outcome at day 90: an analysis of the Virtual International Stroke Trials Archive (VISTA) database. Stroke 43 (2012), 1266–1272.
19. 19 Cumming, T.B., Bernhardt, J., Linden, T., The Montreal Cognitive Assessment: short cognitive evaluation in a large stroke trial. Stroke 42 (2011), 2642–2644.
20. 20 Kappetein, A.P., Head, S.J., Genereux, P., et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60 (2012), 1438–1454.
21. 21 Chieffo, A., Giustino, G., Spagnolo, P., et al. Routine screening of coronary artery disease with computed tomographic coronary angiography in place of invasive coronary angiography in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv, 8, 2015, e002025.
22. 22 Dangas, G.D., Lefevre, T., Kupatt, C., et al. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial. J Am Coll Cardiol 66 (2015), 2860–2868.
23. 23 Bernelli, C., Chieffo, A., Montorfano, M., et al. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation. J Am Coll Cardiol Intv 7 (2014), 140–151.
24. 24 Giustino, G., Latib, A., Panoulas, V.F., et al. Early outcomes with direct flow medical versus first-generation transcatheter aortic valve devices: a single-center propensity-matched analysis. J Interv Cardiol 28 (2015), 583–593.